NASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis $6.61 +0.14 (+2.16%) Closing price 04:00 PM EasternExtended Trading$6.54 -0.07 (-1.04%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 4D Molecular Therapeutics Stock (NASDAQ:FDMT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FDMT alerts:Sign Up Key Stats Today's Range$6.09▼$6.6550-Day Range$3.71▼$7.2752-Week Range$2.23▼$17.41Volume646,729 shsAverage Volume712,709 shsMarket Capitalization$308.69 millionP/E RatioN/ADividend YieldN/APrice Target$30.40Consensus RatingModerate Buy Company Overview 4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches. 4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. Notable programs target inherited retinal disorders—such as X-linked retinitis pigmentosa and achromatopsia—as well as investigational candidates for neuromuscular and metabolic diseases. By tailoring capsid design to specific tissues, the company seeks to optimize safety and efficacy in patient populations with high unmet medical need. To support its research and development efforts, 4D Molecular Therapeutics engages in collaborations with academic institutions and industry partners in the United States and Europe. The company completed its initial public offering in October 2017, trading on the NASDAQ under the symbol FDMT, and has used the proceeds to advance its clinical and preclinical programs. The company is led by President and Chief Executive Officer John J. Falcon, whose leadership team comprises experienced professionals in gene therapy development, regulatory affairs and commercial strategy. Under Falcon’s guidance, 4D Molecular Therapeutics continues to advance its innovative platform with the goal of delivering transformative treatments to patients suffering from rare genetic disorders.AI Generated. May Contain Errors. Read More 4D Molecular Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreFDMT MarketRank™: 4D Molecular Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 628th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst Coverage4D Molecular Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about 4D Molecular Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.84) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 4D Molecular Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.87% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 11.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.87% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 11.89%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.91 News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for FDMT on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows2 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of 4D Molecular Therapeutics is held by insiders.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 4D Molecular Therapeutics' insider trading history. Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FDMT Stock News Headlines4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA ReadinessSeptember 2 at 8:00 AM | globenewswire.com4DMT to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.September 4 at 2:00 AM | Traders Agency (Ad)4DMT Announces New Employment Inducement GrantsAugust 15, 2025 | globenewswire.com4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement LandscapeAugust 12, 2025 | msn.com4D Molecular Therapeutics, Inc.: 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesAugust 11, 2025 | finanznachrichten.de4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesAugust 11, 2025 | finance.yahoo.com4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesAugust 11, 2025 | globenewswire.comSee More Headlines FDMT Stock Analysis - Frequently Asked Questions How have FDMT shares performed this year? 4D Molecular Therapeutics' stock was trading at $5.57 at the beginning of 2025. Since then, FDMT shares have increased by 18.7% and is now trading at $6.61. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) issued its quarterly earnings data on Monday, August, 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.10. The firm earned $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 40.15% and a negative net margin of 594,375.81%. When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? Top institutional shareholders of 4D Molecular Therapeutics include BVF Inc. IL (9.91%), Federated Hermes Inc. (3.60%), Geode Capital Management LLC (1.98%) and Raymond James Financial Inc. (0.98%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Scott Bizily and Robert Young Kim. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 4D Molecular Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings8/11/2025Today9/04/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FDMT CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for 4D Molecular Therapeutics$30.40 High Price Target$44.00 Low Price Target$6.00 Potential Upside/Downside+359.9%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.87 million Net Margins-594,375.81% Pretax Margin-594,375.75% Return on Equity-40.15% Return on Assets-36.43% Debt Debt-to-Equity RatioN/A Current Ratio8.75 Quick Ratio8.75 Sales & Book Value Annual Sales$40 thousand Price / Sales7,717.18 Cash FlowN/A Price / Cash FlowN/A Book Value$11.05 per share Price / Book0.60Miscellaneous Outstanding Shares46,700,000Free Float42,219,000Market Cap$308.69 million OptionableOptionable Beta2.86 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:FDMT) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredNewegg (NEGG) Earns BULLISH Rating – Up 934%The last time he shared a free AI stock pick like this, it soared 100%.Chaikin Analytics | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.